2025年3月10日，Belite Bio (NASDAQ: BLTE)在Leerink 2025年全球医疗大会上发表演讲，首席科学官Nathan Mata分享了其药物TINlarabant在治疗Stargardt病和地理性萎缩 (GA)方面的第二期临床试验成果，同时也讨论了监管挑战和未来市场准入计划。

仁新(6696)今(27)日代子公司Belite Bio, Inc(那斯达克股票交易代码：BLTE，以下简称Belite)公告，旗下LBS-008(Tinlarebant)针对青少年斯特格病变(STGD1)全球临床三期试验(DRAGON)期中分析，获资料及安全监测委员会(D ...

Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, ...

In a report released on February 28, Bruce Jackson from Benchmark Co. reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE – Research Report), ...

27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Belite Bio has a 1-year low of $31.00 and a 1-year high of $86.53. The stock has a market capitalization of $1.82 billion, a P/E ratio of -51.53 and a beta of -1.59.

27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics ...

Tuesday - Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous target of $57.00, while reiterating a Buy rating on the stock.

Belite Bio reports interim analysis results from phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease patients: San Diego Monday, March 3, 2025, 18:00 Hrs [IST] Bel ...